Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Toceranib is a small molecule, multi-targeted receptor tyrosine kinase inhibitor that is structurally related to sunitinib (Item No. 13159).1 It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit.1 Moveover, toceranib blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death.1 It is active in vivo and is commonly used against solid tumors in dogs.2,3
WARNING This product is not for human or veterinary use.
1. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 100(2), 585-593 (2002).
2. Preliminary evidence for biologic activity of toceranib phosphate (Palladiar) in solid tumours. Vet. Comp. Oncol. 10(3), 194-205 (2012).
3. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit. Rev. Oncol. Hematol. 88, 187-197 (2013).